The verdict
Our read at a glance.
Whether repository corticotropin (Acthar Gel) earns its use and its very high price beyond the one indication with strong evidence (infantile spasms), given that for most of its grandfathered uses it largely works by raising the body's own steroids, which cheaper corticosteroids do directly.
- The signal
- For infantile spasms, controlled trials support ACTH as an effective first-line treatment. For its many other approved uses, carried over from a 1952 approval, modern controlled evidence that it beats far cheaper corticosteroids is thin, and most of its effect comes from stimulating the body's own cortisol. Its manufacturers faced major legal settlements over pricing and marketing.
- The unknown
- Whether ACTH has a meaningful direct anti-inflammatory effect beyond simply raising steroids, the claim used to justify its premium over corticosteroids, remains unproven in head-to-head outcomes for most conditions.
- Our read
- A real hormone with one strong use and a long tail of expensive, thinly-supported ones. Repository corticotropin (Acthar Gel) genuinely helps in infantile spasms, but for most of its grandfathered approvals it mainly raises the body's own steroids, something cheap corticosteroids do directly, and it became infamous for its price and marketing. Read it as approved but context-dependent: strong for one childhood seizure disorder, hard to justify over steroids elsewhere.
The mechanism
How it works.
ACTH (adrenocorticotropic hormone) is the pituitary's signal to the adrenal glands; it binds a receptor on the adrenal cortex and tells it to pour out cortisol and related steroids. Repository corticotropin is a long-acting, pig-derived form of ACTH suspended in gelatin so it releases slowly after injection. Because its main action is to crank up the body's own steroid output, for most conditions it is essentially an indirect, expensive way to deliver a steroid effect. Its makers argue it also calms inflammation directly through other melanocortin receptors on immune cells, which is the rationale for using it instead of plain steroids, but that added benefit is not well proven. In infantile spasms, a severe seizure disorder of babies, ACTH has a genuine, trial-supported first-line role.
Safety & regulatory boundary
The consequential part.
Because it works largely by driving the body to make corticosteroids, ACTH carries the same risks as steroid treatment, raised blood sugar and blood pressure, fluid retention, mood changes, infection risk, and bone loss with long use, plus allergy risk as a pig-derived product. It is FDA-approved through a grandfathered 1952 approval for a broad list of conditions, but strong evidence is concentrated in infantile spasms; for most other uses cheaper corticosteroids are the usual choice. It is a prescription drug given by injection, and its history includes large legal settlements over price increases and marketing. It is distinct from cosyntropin, the short synthetic ACTH fragment used only as a diagnostic test.
What's next
What we're watching.
Head-to-head trials versus corticosteroids in its non-spasm indications, any evidence for a steroid-independent benefit, and how pricing and access evolve after the manufacturer's legal and financial troubles.
Context
Why this is discussed.
Acthar Gel is the textbook case of a drug whose price and marketing outran its evidence. It is a real hormone with one genuinely strong use, calming the severe infant seizures called infantile spasms, but it is also approved for a long list of older conditions where cheaper steroids usually do the same job, and it became one of the most expensive and controversial drugs in the US.
The evidence base
9 cited references.
Regulatory & labels1
Mallinckrodt ARD LLC (FDA label) · 2025
Indexed literature (PubMed)8
Wong M et al. · Pediatr Neurol · 2001
Kelley SA et al. · Curr Neurol Neurosci Rep · 2018
Messer R et al. · Semin Neurol · 2020
Chen B et al. · J Am Soc Nephrol · 2023
Riikonen R · Pediatr Neurol · 2020
Riikonen R · J Child Neurol · 2004
Kutz CF et al. · Neurodegener Dis Manag · 2018
Kaplan J et al. · Clin Drug Investig · 2023
Keep reading